Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies

21 Mar 2025

Abstract excerpt

Immunotherapy has emerged as a preeminent force in the domain of cancer therapeutics and achieved remarkable breakthroughs. Nevertheless, the high resistance has become the most substantial impediment restricting its clinical efficacy. Beta-2 microglobulin (B2M), the light chain of major histocompatibility complex (MHC) class I, plays an indispensable part by presenting tumor antigens to cytotoxic T lymphocytes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40191187
DOI: 10.3389/fimmu.2025.1512509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategiesPMID 40191187Read ↗

Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.Semantic proximity Read ↗

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Semantic proximity Read ↗

Decipher β2-microglobulin: gain- or loss-of-function (a mini-review).Semantic proximity Read ↗

B2M mutation paves the way for immune tolerance in pathogenesis of Epstein-Barr virus positive diffuse large B-cell lymphomasSemantic proximity Read ↗

The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapySemantic proximity Read ↗

The Implication and Significance of Beta 2 MicroglobulinSemantic proximity Read ↗

Resistance to checkpoint blockade therapy through inactivation of antigen presentationSemantic proximity Read ↗

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable PatientsSemantic proximity Read ↗

The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.Semantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

MHC heterogeneity and response of metastases to immunotherapy.Semantic proximity Read ↗

Biological Consequences of MHC-II Expression by Tumor Cells in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.